Steroids could do more harm than good in treating coronavirus

10-Feb-2020 - United Kingdom

steroids should be avoided in the treatment of the current novel coronavirus, experts have advised.

A commentary article published in The Lancet concludes that, based on evidence from previous outbreaks of similar types of infection such as SARS, steroids provide little benefit to patients and could do more harm than good.

They say that clinicians should still administer the treatment for conditions such as asthma and other inflammatory diseases.

Steroids are often used by doctors to reduce inflammation, which is present in the lungs of patients with novel coronavirus. Lung inflammation was observed during the SARS and MERS outbreaks, which were caused by coronaviruses.

However, steroids also impair the immune system's ability to fight viruses and other infections that often develop in patients with life-threatening illness. Experts say that, on balance, using the drugs could cause significant harm.

One retrospective study of critically-ill patients with MERS found that almost half of the people that received steroids needed additional treatments such as assistance in breathing, drugs to increase blood pressure, and a form of dialysis. Those given steroids were found to take longer to clear the virus from their bodies.

Other studies found that steroids caused harm in the SARS outbreak, with the virus still present in those who took the drugs up to three weeks after infection.

Dr J. Kenneth Baillie, lead author of the commentary article and Academic Consultant in Critical Care Medicine at University of Edinburgh, said: "During this current coronavirus outbreak clinicians are faced with some tough decisions on how to treat people who have been infected. After looking carefully at what evidence is available, we would advise that steroids should not be used for treatment of lung injury caused by this new virus. If steroids are used, it should be as part of a clinical trial so that we can find out if they are helping or harming patients."

Other news from the department science

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Defective immune cells in the brain cause Alzheimer’s disease - Scientists are studying the role of immune cell activation in Alzheimer's disease

Defective immune cells in the brain cause Alzheimer’s disease - Scientists are studying the role of immune cell activation in Alzheimer's disease

Actelion and Roche enter into autoimmune disorder collaboration

Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma

Transplanted hematopoietic stem cells reverse damage caused by neuro-muscular disorder

Transplanted hematopoietic stem cells reverse damage caused by neuro-muscular disorder

Innovative bioreactor research processes and cryotechnologies improve active ingredient tests using human cell cultures - This is paving the way for efficient real-world use of these cell cultures in toxicity testing and drug discovery

Innovative bioreactor research processes and cryotechnologies improve active ingredient tests using human cell cultures - This is paving the way for efficient real-world use of these cell cultures in toxicity testing and drug discovery

1 g cut in daily salt intake could ward off nearly 9 million cases of stroke/heart disease in China - And save 4 million lives by 2030, modelling study suggests

1 g cut in daily salt intake could ward off nearly 9 million cases of stroke/heart disease in China - And save 4 million lives by 2030, modelling study suggests

Genetically engineered stem cells to boost cancer immunotherapy - Researchers sign an agreement to research the production of CAR-NK cells, which are easier to produce than CAR-T cells used successfully in immunotherapy

Genetically engineered stem cells to boost cancer immunotherapy - Researchers sign an agreement to research the production of CAR-NK cells, which are easier to produce than CAR-T cells used successfully in immunotherapy

A new biomass-focused research center in Sao Paulo

Movetis wins two out of three categories at the PharmaVentures European Deals 2010 Awards

Monsanto and Evogene Extend Collaboration on Yield and Stress Research

CSL Behring - King of Prussia, USA

CSL Behring - King of Prussia, USA

Novartis begins shipment of Fluvirin seasonal influenza vaccine for the U.S. market ahead of schedule - Providing 30 million doses of Fluvirin vaccine in the U.S., to support the annual seasonal influenza vaccination campaign